

Treatment Subcommittee
Drinking Water Quality Institute
June 8, 2007

Attendees: Paul LaPierre, Russell Ford, Laura Cummings, Carol Storms, Barker Hamill, Ravi Patraju, Karen Fell, and Kristin Hansen

1. The Treatment Subcommittee members' and NJDEP staff's roles in the subcommittee were reviewed. In addition to the Drinking Water Quality Institute (DWQI) members, K. Hansen and K. Fell will be the representatives for the Bureau of Safe Drinking Water. R. Patraju is the representative for Eileen Murphy, Division of Science Research and Technology.
2. Copies of the June 8, 2007 memo from the Testing Subcommittee to the Treatment Subcommittee were provided. The memo refers four A-280 chemicals (1,1,2-Trichloroethane, Vinyl Chloride, n-Hexane, and Formaldehyde) to the Treatment Subcommittee upon completion of its review, in which they recommend: the PQLs of these four chemicals may be lowered due to improved analytical capabilities. In addition, since there have been no improvements in the analytical testing capability for Chlordane, Tetrachloroethylene (PCE), and 1,1,2,2-Tetrachloroethane, the Testing Subcommittee recommends no change in their respective PQL.

The Treatment Subcommittee reviewed the memo and focused on the difference between the two lists of chemicals. The two lists consist of those with changes to the PQL and those with no changes to the Health Based number and PQL.

While discussing the memo, a question was asked whether or not the DWQI has a role in the Black and Veatch Unregulated Contaminant Study.

B. Hamill indicated that the DWQI will be kept informed of the status and when the three studies are completed, they will be forwarded to the DWQI to assist in determining the process of moving forward.

In addition, it was mentioned that some rule changes will be made to the New Jersey Safe Drinking Water Act for September 2009, and the NJDEP will be reaching out to the DWQI to discuss the proposed rule revisions.

3. An assessment of the current treatment technologies available for the chemicals being referred by the Testing Subcommittee will need to be performed. The NJDEP would like to contract consulting services for the treatment expertise. The subcommittee agreed. B. Hamill asked if the subcommittee has any specific ideas of what to include in the study. The subcommittee recommended including those chemicals that have not yet been referred to Treatment by Testing.

B. Hamill also explained that the consultant would review the cost of treatment, which can not be a determining factor, but must be addressed in any rule recommendation.

NJDEP anticipates drafting a scope of work, using the scope of work previously drafted for the synthetic organic compounds. NJDEP will provide the scope of work to the Treatment Subcommittee for their review and comment. NJDEP anticipates having the scope of work drafted by July 6, 2007.

4. The next meeting is to be announced.